Oncotarget

Case Reports:

The benefit of everolimus in recurrent/epithelioid angiosarcoma patients: Case reports and literature review

Shi-Long Zhang _, Li Liang, Yuan Ji, Zhi-Ming Wang and Yu-Hong Zhou

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:95023-95029. https://doi.org/10.18632/oncotarget.21832

Metrics: PDF 1125 views  |   HTML 1345 views  |   ?  


Abstract

Shi-Long Zhang1, Li Liang2, Yuan Ji3, Zhi-Ming Wang2 and Yu-Hong Zhou2

1 Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China

2 Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China

3 Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China

Correspondence to:

Yu-Hong Zhou, email:

Zhi-Ming Wang, email:

Keywords: recurrence/metastatic epithelioid angiosarcoma; everolimus; targeted therapy

Received: August 15, 2017 Accepted: September 25, 2017 Published: October 15, 2017

Abstract

Epithelioid angiosarcoma (EA) is a kind of rare malignant soft tissue sarcoma, with high recurrence/metastatic rate and poor prognosis. To date, no effective standardized treatment regimen has been available for patients with recurrence/metastatic EA. Everolimus is an oral rapamycin derivative that highly inhibits the mechanistic target of rapamycin(mTOR) signal pathway. Previous studies have suggested that everolimus is effective and safe in some soft tissue sarcoma. We reported two cases with recurrence/metastatic EA, who received everolimus after failure of surgery, radiotherapy, chemotherapy or interventional therapy. Two cases obtained clinical benefit within 1 week, and were evaluated as partial response (PR). The progression free survival (PFS) time was nearly 12.0 and 6.0 months, respectively. The overall survival (OS) time was 18.0 and 10.0 months, respectively. The main adverse event was stomatitis syndrome (grade 1-2), which was well controllable and tolerable. It indicated that everolimus may be more beneficial for recurrence/metastatic EA patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21832